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Abstract: Signiﬁ  cant advances in the management of chronic hepatitis B (CHB) have been 
made over the past decade. During this period we have witnessed improvements in survival as 
well as reduction of disease progression in CHB patients due to the introduction of effective 
antiviral therapy. The need for effective antiviral therapy is underscored by the results of the 
REVEAL-HBV study in which 3653 hepatitis B virus (HBV) carriers were followed over 12 
year period. This study demonstrated that a persistently elevated serum HBV DNA level was 
the most important risk factor for the development of hepatocellular carcinoma (HCC). The 
ultimate goal of antiviral therapy for CHB patients should include halting the progression to 
cirrhosis and its life threatening complications and in preventing/reducing the development of 
HCC. An earlier study of 651 CHB patients with cirrhosis or advanced ﬁ  brosis from countries 
in Asia also demonstrated that treatment with lamivudine (LVD) not only delayed disease pro-
gression but also reduced the development of HCC. These landmark studies reafﬁ  rm the need 
for active antiviral therapy for CHB. Current treatment options for patients with CHB include 
interferon and nucleos(t)ide analogues. As we gain experience with these agents, it has become 
increasingly clear that long-term therapy beneﬁ  ts patients with CHB.
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Case reports
Since 1983, the author (HWH) has followed 6 families in which 16 children were 
identiﬁ  ed as Hepatitis B surface antigen (HBsAg)-positive during high school or in 
college. Further investigation revealed all 16 children were born to HBsAg(+) moth-
ers and were likely infected during childbirth. During subsequent years, HBsAg(+) 
members of 5 families were treated with antiviral agents, including LVD, adefovir 
(ADV), tenofovir (TDF) or entecavir (ETV) and they have remained well on therapy 
with normal liver function and liver imaging studies. Three children of the 6th family, 
however, did not receive therapy. Over the ensuing years, these children (now in their 
40’s) remained asymptomatic although their liver enzymes were occasionally elevated. 
Ultimately, one of the three children, after only two weeks of fatigue, was found to 
have an advanced HCC with cirrhosis and splenomegaly. He, at the age of 44, passed 
away within 6 months of his HCC diagnosis. Immediately, the two remaining children 
elected to start antiviral therapy.
 In 2000, a 58 year-old Korean American man brought his older brother to Thomas 
Jefferson University Hospital for treatment of HCC. He himself had just completed 
interferon therapy for HBV and assumed he was cured. While his brother was undergo-
ing cryosurgery he himself had an abdominal imaging and was found to have a 4 cm 
HCC in the right lobe of the liver. Laboratory studies revealed that he was Hepatitis B 
e antigen (HBeAg)-positive and had high levels of HBV DNA. He received radiofre-
quency tumor ablation and was started on LVD. He developed LVD resistance 4 years Therapeutics and Clinical Risk Management 2007:3(4) 606
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later, is currently on tenofovir (TDF) after suboptimal response 
to ADV. Now at the age of 64, he has remained a very suc-
cessful businessman with normal liver function, undetectable 
serum HBV DNA and without recurrent or new HCC.
A 49 year-old Asian American man received IFN therapy 
for 4 months (3/94–7/94) but without HBeAg conversion. 
He received no therapy despite having ALT elevation until 
5/96 when LVD (as Epivir) became available. LVD therapy 
was discontinued in 11/99 after HBeAg seroconversion 
and he relapsed in 9/02. Retreatment with LVD resulted in 
undetectable HBV DNA and LVD therapy was discontinued 
in 11/04. He is now 61 years old with normal liver function 
with undetectable HBV DNA and remains well.
The cases described above clearly illustrate how antiviral 
agents could successfully halt the progression of liver disease 
or development of new HCC in patients with CHB.
Introduction
There are nearly 350 million HBV carriers worldwide (Lee 
1997). These carriers are at risk for development of cirrho-
sis, HCC and death. Recently, Chen et al (2006) in Taiwan 
reported the results of their 12 year follow-up study, the 
REVEAL-HBV study (Risk Evaluation of Viral load Eleva-
tion and Associated Liver disease/cancer). They found that 
elevated serum HBV DNA level  10,000 copies/mL was the 
most important risk factor for HCC independent of HBeAg, 
serum alanine aminotransferase (ALT) and liver cirrhosis. 
In this elegant study the authors followed 3653 HBsAg(+) 
carriers (aged 30–65 years) for a mean follow-up of 11.4 
years and during this period 164 persons developed HCC. 
The incidence of HCC increased with serum HBV DNA level 
at study entry in a dose-response relationship ranging from 
108/100,000 person-years for an HBV DNA level of  300 
copies/mL to 1152/100,000 person-years for an HBV DNA 
level of  1,000,000 copies/mL.
Also, Liaw et al (2004), in a trial of 651 CHB patients 
with cirrhosis or advanced ﬁ  brosis from several countries 
in Asia, randomized 2/3 of patients to receive LVD and 1/3 
of patients to receive placebo. In less than 3 years on study 
the authors observed that those who received LVD not only 
showed delayed disease progression but also had reduced 
incidence of HCC compared to those on placebo. These two 
landmark studies reafﬁ  rm the need for an active approach for 
patients with CHB with an antiviral therapy.
The aims of treatment of CHB are to achieve sustained 
suppression of HBV replication and remission of liver dis-
ease. The end points include normalization of serum ALT 
level, undetectable serum HBV DNA by an ampliﬁ  ed assay, 
loss of HBeAg, with or without detection of anti-HBe, and 
improvement of liver histology (Lok and McMahon 2004). 
The ultimate long-term goal of therapy is to prevent hepatic 
decompensation, to reduce or prevent progression to cirrhosis 
and/or HCC, and to prolong survival (Liaw et al 2005).
In 1992, interferon alpha (IFN-α) was ﬁ  rst introduced for 
the treatment of CHB. As of November 2006, there are six 
FDA approved drugs available for the treatment of CHB in 
the United States, including two formulations of interferon 
and four oral nucleos(t)ide agents.
With multiple therapeutic agents available, there is a great 
need for physicians to have sufﬁ  cient knowledge to provide 
the best choice of treatment for their patients. While these 
drugs are all highly effective, there are differences in drug 
safety, cost, drug resistance and risks of disease ﬂ  are from 
premature discontinuation of therapy or from poor compli-
ance on the part of patients. In addition, the disease may 
recur even after treatment and therefore, close follow-up after 
the completion of therapy is important. Furthermore, close 
monitoring for early detection of HCC is essential during 
and after the treatment. As strong advocates for an active and 
earliest possible intervention for CHB with antiviral agents, 
the efﬁ  cacy, the advantages and disadvantages of currently 
available therapeutic agents are being examined.
Interferon-α2b
Interferon-α2b (IFN-α2b) became available in 1992 and 
remained the only FDA approved agent for the treatment of 
CHB until 1998. IFN-α2b has direct effects on the immune 
system, including enhanced expression of HLA class I mol-
ecules and stimulation of CD8+ cytotoxic T-cell activity. 
The duration of treatment ranges between 4 to 6 months by 
subcutaneous injection of 5 million units daily or 10 million 
units three times weekly. This regimen results in HBeAg loss 
in 30%–40% of patients and clearance of HBsAg in 10% of 
patients. Studies from North America and Europe have shown 
HBeAg loss in 30%–35% of patients who are treated with 4 
to 6 months of interferon-α2b (Perrillo et al 1990).
In HBeAg(–) CHB, the response has been deﬁ  ned as 
undetectable serum HBV DNA by unampliﬁ  ed assays and 
normalization of ALT level. Results of four randomized trials 
involving a total of 86 IFN-α2b treated patients and 84 controls 
showed that the end-of-treatment response ranged from 38 to 
90% in treated patients compared with only 0% to 37% of 
controls. Longer duration of treatment up to 24 months may 
improve the rate of sustained response (Lok and McMahon 
2001). A study from Taiwan showed that 6–10 months IFN 
therapy in HBeAg(–) CHB patients had an end-of-treatment Therapeutics and Clinical Risk Management 2007:3(4) 607
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response of 57% (vs 18% of controls) and 6 months sustained 
response of 30% (vs 7%) (Lin et al 2001).
However, therapeutic effect of IFN-α2b in Asian patients 
has been far inferior to the results seen among European 
patients, possibly related to a longer duration of infection 
(Asians are often infected perinatally) and different HBV 
genotypes. Lok et al (1988) reported that IFN-α2b has little 
long-term effect in suppressing HBV replication in Chinese 
patients with CHB. Interestingly, Martin et al (1998), in 
their prospective controlled study with IFN-α2b comparing 
Caucasian and Asian-American patients with CHB, found no 
difference in clearance of HBeAg loss or HBV DNA (62% 
vs 60%) except for a shorter durability of response in Asian-
American patients. The Asian American patients in this study 
were noted to have acquired HBV infection during adulthood. 
Side effect of IFN-α2b include ﬂ  u-like symptoms, depression, 
renal failure, heart failure, and alopecia and others.
Pegylated interferon-α
Recently, pegylated forms of IFN-α2a (PegIFN-α2a) have 
been developed. Because of a decreased renal clearance 
rate, PegIFN-α2a is administered weekly. Studies suggest 
that PegIFN-α2a is more effective than standard IFN-α. 
The side effect proﬁ  le of PegIFN-α2a is similar to that of 
standard IFN-α. PegIFN α2a in doses of 180 µg weekly has 
been used for 48 weeks in both HBeAg(–) (Lau et al 2005) 
and HBeAg(–) CHB (Marcellin et al 2004). The major-
ity of 814 HBeAg(+) patients studied by Lau et al (2005) 
were Asian (87%). Most of them were infected with HBV 
genotype B or C. At the end of 48 week treatment, HBeAg 
seroconversion occurred in 27% of patients, and increased 
to 32% at the end of 6-month post-treatment observation 
period (Lau et al 2005). For HBeAg(–) 537 CHB patients, 
PegIFN-α2a in doses of 180 µg weekly for 48 weeks with or 
without LVD produced better results (HBV DNA decrease, 
ALT normalization) than LVD alone at the end of 6 months 
follow up off treatment (Marcellin et al 2004).
Nucleos(t)ide analogues
LVD, ADV, entecavir (ETV) and telbivudine (LdT) are all 
orally administered drugs currently available for treatment of 
CHB. In addition, several candidates, such as emtricitabine, 
clevudine, TDF, pradefovir and others are in the ﬁ  nal stages 
of clinical trials.
Lamivudine (LVD)
LVD is a potent inhibitor of viral replication, convenient to 
administer, and has very few side effects. LVD is given in 
a dose of 100 mg (or 150 mg) daily. For HBeAg(+) CHB, 
a 2 year course of LVD has resulted in further increase of 
HBeAg seroconversion from 17% at 1 year to 27% at 2 years 
(Liaw et al 2000) and 47% after 4 years (Chang et al 2004). 
With LVD therapy, the majority of patients develop unde-
tectable HBV DNA by PCR assay. However, LVD therapy 
should be continued until HBeAg seroconversion which 
may take months to years even after HBV DNA has become 
undetectable. The optimal duration of LVD administration 
following HBeAg seroconversion remains undetermined at 
present time. Nonetheless, it has generally been agreed that 
it needs to be longer than 6 months due to frequent relapses 
observed after cessation of therapy. The half-life of HBV-
infected hepatocytes is reported to be 10–100 days with a 
mean of 16 days (Nowak et al 1996) and Zeuzem et al (1997) 
in their study with LVD described that the half life of HBV 
infected cells is longer than 100 days and 1 year treatment 
of LVD will not reduce the number of infected cells to less 
than 10% of its initial value. Ryu et al (2003) reported results 
of their study in which patients were continued on LVD 
therapy for 6, 12 and 24 months after the HBeAg conver-
sion. They observed relapse rates 2 years after the cessation 
of LVD therapy to be 57%, 51% and 29% of patients who 
received 6, 12 and 24 months of additional LVD therapy 
respectively. More importantly, if LVD is stopped before 
HBeAg seroconversion even with undetectable HBV DNA, 
virus returns often accompanied with ALT ﬂ  are which can 
be severe at times.
For HBeAg(–) patients, the length of continued therapy 
is determined from the time point when HBV DNA becomes 
undetectable by the available PCR assay. Currently, the rec-
ommendation is to continue treatment for minimum 2 more 
years after HBV DNA becomes undetectable. Despite this, 
there are relapses even after completion of the recommended 
length of therapy. Therefore, the efﬁ  cacy of life-long treat-
ment for the management of HBeAg(–) CHB is currently 
under investigation (Perrillo 2006).
Although it has been well established that HBeAg 
loss correlated positively with pretreatment ALT levels 
(Perrillo et al 2002) in LVD therapy, other studies with 
LVD (Hann et al 2005) and ETV (Rosmawati et al 2003), 
did not ﬁ  nd signiﬁ  cant correlation between pretherapy ALT 
and the virological response. Hann et al (2005) compared 
LVD therapy results for 317 HBeAg(+) and HBeAg(–) CHB 
patients with active viral replication with regard to differ-
ent pretreatment ALT levels (upper normal limit of ALT 
40 U/L). In this study, the loss of HBeAg were 40%, 57% 
and 61% for groups with pretreatment ALT  upper limit Therapeutics and Clinical Risk Management 2007:3(4) 608
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of normal (ULN), 1–2 × ULN and  2 × ULN, respectively. 
However, these differences were not statistically signiﬁ  cant. 
Also, in both HBeAg(+) and HBeAg(–) patients, there were 
no signiﬁ  cant differences in the loss of HBV DNA among 
the three ALT groups.
Resistance to lamivudine (LVD)
Lamivudine (LVD) treatment of greater than 1 year has 
been associated with a steady increase in LVD resistance 
with reported rates of resistance of 38% and 65% at 2 and 
5 years, respectively (Lok et al 2003) For LVD-resistant 
patients it is generally recommended to overlap ADV with 
LVD for some time during the switch to ADV. The role of 
continuing LVD treatment in patients with LVD-resistant 
HBV who are receiving adefovir is controversial. A pooled 
study of 467 patients with LVD resistant HBV demonstrated 
that resistance to ADV was seen only in those who stopped 
LVD (Snow et al 2005). Lee et al (2006) also found 18% 
ADV resistance in LVD resistant CHB patients who received 
ADV monotherapy. In recent reports on both HBeAg(+) and 
HBeAg(–) LVD-resistant CHB patients, the combination 
of LVD and ADV showed a superior virologic response 
when compared to ADV monotherapy (Barbon et al 2006; 
Lampertico et al 2006).
Prolonged treatment: beneﬁ  ts 
and limitations
Prolonged treatment with LVD is generally well tolerated. 
In patients with HBeAg(–) CHB. Prolonged LVD therapy 
(3.8 ± 1.4 years) has been associated with improved sur-
vival and reduction in the risk of liver related complica-
tions, seemingly equivalent to that observed in sustained 
responders to IFN-α therapy (Papatheodoridis et al 2005). 
A major problem complicating prolonged or long-term 
therapy with LVD, however, is the progressive increase in 
drug resistance. Recent study by Chae and Hann (2006), 
however, suggested that patients with a baseline HBV DNA 
level  6 log10 copies/mL have a much lower incidence of 
LVD resistance; 3% at 1 year, 9% at 2 years and 32% at 3 
years of LVD therapy. In contrast, patients with a baseline 
HBV DNA  6 log10 copies developed LVD resistance at a 
rate of 10% at 1 year, 36% at 2 years and 74% at 3 years. 
Therefore, patients with low baseline HBV DNA may 
still beneﬁ  t from long-term LVD therapy. LVD is also the 
least expensive among all antiviral drugs. The majority of 
HBV patients live in HBV endemic countries and these 
countries are also economically disadvantaged. Given that 
CHB management required long-term therapy, the cost of 
treatment can become an important personal and national 
issue (especially in hyperendemic regions).
Adefovir dipivoxil (ADV)
Adefovir dipivoxil (ADV) is the acyclic analogue of dAMP. 
In 2002, ADV received FDA approval for the treatment of 
patients with HBeAg(+) and HBeAg(–) CHB. It is a prodrug 
with enhanced oral availability. ADV has activity in vitro 
against both wild type and LVD-resistant HBV strains. For 
this reason, ADV has been used to treat patients with LVD 
resistance. Monotherapy with ADV 10 mg/day for HBeAg(+) 
patients leads to marked decrease in HBV DNA levels (by 3 to 
4 log10 units), improvements in serum ALT and hepatic histol-
ogy and increased rates of HBeAg seroconversion (Marcellin 
et al 2003). After 3 years of treatment HBeAg loss was 51%, 
HBeAg seroconversion 43% and 56% of patients had unde-
tectable HBV DNA (Marcellin et al 2005). Similar trials have 
been carried out in patients with HBeAg(–) CHB, in whom 
improvements in serum ALT and liver histology occurred in 
more than 60% of patients (Hadziyannis et al 2005a).
Long-term treatment of adefovir 
(ADV)
Prolonged treatment with ADV has been reported to be 
associated with an increasing virologic response in HBeAg(+) 
and HBeAg(–) CHB and has been found to be generally safe. 
ADV treatment for 3 years results in an increase in HBeAg 
seroconversion (12 % at year 1, 29 % year 2, and 43% at year 3) 
(Marcellin et al 2005). Three years of continuous treatment also 
has been associated with a progressive decline in serum HBV 
DNA and an increase in the percentage of patients becoming 
HBV DNA negative by PCR in HBeAg(–) CHB (Hadziyannis 
et al 2005b). Serum creatinine should be monitored as slight 
elevations in serum creatinine have been observed in less 
than 2% of patients treated with 10 mg daily for 2 to 3 years 
and rarely require discontinuation of drug. (Hadziyannis et al 
2005b). The resistance proﬁ  le of ADV is better than that of 
LVD. Hadziyannis et al (2005a), in a study of 185 HBeAg(–) 
patients, reported ADV-resistance rates of 3% of patients at year 
2, 11% at year 3, 18% at year 4 and 29% at year 5. However, 
others in a smaller study reported a higher cumulative prob-
ability of resistance to ADV of 22% after 2 years (Fung et al 
2006). The N236T and A181V/T ADV resistant mutants have 
been reported, both of which are sensitive to LVD therapy.
Entecavir (ETV)
Entecavir (ETV) is a cyclopentyl guanine nucleoside 
analogue. ETV blocks HBV replication by inhibiting the Therapeutics and Clinical Risk Management 2007:3(4) 609
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priming of HBV DNA polymerase as well as the synthesis 
of the first and second strand of HBV DNA. In a recent 
study of 715 patients with HBeAg(+)CHB, the mean 
reduction in serum HBV DNA from baseline to week 48 
was greater with ETV 0.5 mg than with LVD 100 mg (6.9 
vs. 5.4 log10 copies/mL, p   0.001) (Chang et al 2006b). 
However, HBeAg seroconversion (or HBeAg loss) at 48 
weeks between the two arms were similar; 21% (22%) 
for ETV and 18% (20%) for LVD. Histologic improve-
ment after 48 weeks was observed more frequently in 
the ETV group (72%) and than in the LVD group (62%). 
Virological rebound during the first years of drug therapy 
was observed in 2% of the ETV group compared with 18% 
of LVD group. Genotype analysis of isolates obtained at 
week 48 from the six ETV-treated patients revealed no 
emerging substitutions compared with baseline samples. 
No resistance to ETV was reported 48 weeks in treatment 
naïve patients and less than 1% at year 3.
In a study of 648 patients with HBeAg(–) CHB, 
more patients in the ETV group than in the LVD group 
had undetectable HBV DNA at week 48 (90% vs. 72%). 
Patients treated with ETV had statistically significant 
improvements in the mean reduction of serum HBV DNA 
levels from baseline to week 48 when compared with 
patients on LVD therapy (5.0 vs 4.5 log10 copies/ml, 
p   0.001) (Lai et al 2006).
ETV has also been shown to be effective against both 
LVD-resistant HBV and wild type. One mg is the most 
effective dose for patients who failed to respond to LVD 
as shown in a study with 182 subjects (Chang et al 2005 ). 
ETV resistance emergence in ETV-treated nucleoside naïve 
patients over a 4-year period was only 0.8%. However, the 
rate of ETV resistance increased to 1, 10, 32 and 39.5% 
at year 1, 2, 3, and 4 in lamivudine refractory patients 
(Colonno et al 2007). In a recent study patients with CHB 
were randomized to receive open label ETV 0.5 mg/day 
and ADV 10 mg/day and assessed for reductions in HBV 
DNA levels (Leung et al 2006). By week 24, ETV-treated 
patients achieved a mean log HBV DNA reduction of 6.97 
compared to 4.84 for ADV treated patients. Undetectable 
HBV DNA ( 300 copies/mL by PCR) was achieved by 
week 24 in 45% of ETV-treated and 13% of ADV-treated 
patients. A recent 3 year ETV study demonstrated that by 
week 144, 90% of 122 patients in the study showed unde-
tectable HBV DNA ( 300 copies/ml by PCR), 80% had 
normalization of ALT (ALT  1 × ULN), 33% and 16% of 
patients achieved HBeAg loss and HBeAg seroconversion, 
respectively (Chang et al 2006a).
Telbivudine (LdT or TLV)
Telbivudine (LdT or TLV) is a beta -L-2’deoxythymidine 
which acts as a speciﬁ  c inhibitor of HBV polymerase. In 
a three-arm trial, LdT monotherapy was compared with 
LVD monotherapy and the combination of LdT and LVD 
in patients with HBeAg(+) CHB (Lai et al 2005). At week 
52, LdT monotherapy produced a signiﬁ  cantly greater mean 
log HBV DNA reduction (6.09 vs 4.57 log10 copies/ml), 
undetectable HBV DNA (61% vs 32%) and normalization 
of ALT (86% vs 63%) (all, p   0.05) compared to LVD 
monotherapy. The combination treatment was not better 
than LdT alone. HBeAg seroconversion was 31% for LdT 
and 22% for LVD. Viral breakthrough was 4.5% compared 
to 15.8% for LVD. (Lai et al 2005). In the GLOBE Trial 
1,367 patients with 921 HBeAg(+) and 446 HBeAg(–) CHB 
from 20 different countries were randomized to receive LdT 
or LVD (Lai et al 2006). Patients who received LdT had 
statistically signiﬁ  cant HBV DNA reduction than those who 
received LVD regardless of HBeAg status. Drug resistance 
for HBeAg(+) group was 4.4% for LdT and 9.1% for LVD; 
for HBeAg(–) CHB patients, 2.7% of LdT and 9.8% of LVD 
developed drug resistance. Interestingly, LdT resistance 
mutations were solely M204I whereas LVD resistance 
mutations were a mixture of M204V, M204I and M204V 
+ L180M double mutants.
The efficacy of LdT and ADV was studied in 135 
patients with HBeAg(+) compensated CHB. The HBV 
DNA reduction at week 24 was far better for LdT than 
for ADV (Bzowej et al 2006). Another recent study which 
included both HBeAg(+) and (–) compensated CHB 
patients, investigated whether patients receiving LVD 
therapy would benefit from switching to LdT. Patients 
were randomized to either continue LVD (n = 124) or 
switch to LdT (n = 121) for 1 year. In patients with per-
sistent viremia during LVD therapy, switching to LdT 
was associated with a significantly improved HBV sup-
pression (Gane et al 2006).
Tenofovir disoproxil fumarate 
(TDF)
TDF is an acyclic nucleoside phosphonate (nucleotide) ana-
logue of adenosine 5’-monophosphate. It inhibits HBV DNA 
polymerase and HIV reverse transcriptase, with close chemi-
cal similarity to ADV. At the present time, TDF is FDA-ap-
proved for the treatment of patients with HIV and not for 
those with HBV. The activity of TDF in LVD-resistant HBV 
has been observed in patients coinfected with HIV and HBV Therapeutics and Clinical Risk Management 2007:3(4) 610
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who developed LVD resistance (Nunez et al 2002; Ristig 
et al 2002). Based on these experiences, TDF has been used 
off label for those with severe LVD resistance before the ap-
proval of ADV in 2002. Furthermore, TDF has recently been 
compared with ADV in 40 patients with CHB who became 
LVD resistant. Patients in the TDF group exhibited a more 
rapid decline in HBV DNA during the treatment period, with 
a mean reduction of –4.8 and –6.6 log10 copies/mL at 3 and 
6 months, compared to a mean reduction of .97 and –1.72 
log10 copies/mLat 3 and 6 months respectively in the ADV 
group. (Van Bommel et al 2003, 2004). Hann et al (2006) 
have also observed the similar differences. Of 109 patients 
who developed LVD resistance, 65 were placed on ADV and 
44 on TDF. At 12 months on either therapy, the HBV DNA 
log reduction was 5.03 ± 1.64 for TDF and 2.36 ± 2.37 for 
ADV treated patients (p = 0.001). Furthermore, HBV DNA 
reduction  3 log at 12 month was observed in 63% and 28 
% of the TDF and ADV arms, respectively (p = 0.013).
Characteristics of individual FDA approved drugs are 
listed in Table 1.
Combination therapy
With more antiviral agents becoming available, the future 
directions of CHB treatment may involve combination 
therapy, with the goals of reducing drug resistance, mini-
mizing toxicities and maximizing efﬁ  cacy. Ideal synergistic 
regimen may be combination of two drugs with different 
mechanism. Potential combinations need to be studied in 
large well designed clinical trials.
Although there were suggestions initially that the combina-
tion of LVD and IFN-α may have an additive beneﬁ  t this has 
not yet been conﬁ  rmed in a large scale study (Marcellin et al 
2004). Also the combination of LdT and LVD was not shown 
to be more efﬁ  cacious than LdT monotherapy (Lai et al 2005). 
The combination of emtricitabine and ADV showed more 
improved therapeutic effect and less frequent viral resistance 
Table 1 Characteristics of FDA approved drugs for treatment of hepatitis B
Name  Trade name  Strong points  Weak points  Approved
Interferon  Intron A  •  Finite duration of treatment  •  Signiﬁ  cant side effects  1991
alpha -2b    •  Durable response post-  •  65%–70% fail to respond
       treatment (for responders)  •  Needle injection
    •  No known resistance  •  High cost
Lamivudine  Epivir-HBV  •  Oral  •  Long-term treatment may be needed  1998
(LVD) Zefﬁ  x (Asia)  •  Safe with negligible side effects  •  High incidence of resistance: 9.1%–20%
    •  Least expensive     at yr 1, 70% at yr 5 (esp. those with high
    •  Effective for ADV resistant HBV     baseline HBV DNA)
Adefovir  Hepsera  •  Oral  •  Long-term treatment may be needed  2002
Dipivoxil    •  Effective against LVD-resistant  •  Long-term renal toxicity unknown
(ADV)       HBV and ETV-resistant HBV  •  30% fail to respond
    •  Low resistance: 0 at yr 1, 2% at  •  Less potent than LVD or ETV
       yr 2, 7% at yr 3, 15% at yr 4
Entecavir  Baraclude  •  Oral  •  Long-term safety and efﬁ  cacy unknown  2005
(ETV)    •  Potent viral suppression: greater  •  Risk of carcinogenicity in rodents (in 
        than LVD or ADV      very high doses)
    •  Effective for LVD-resistant HBV  •  Cost  ADV  TLV  LVD
    •  Resistance: 0.8% at yr 4 for
       treatment-naïve patients, 39.5% at
       yr 4 for LVD-resistant HBV 
Pegylated  Pegasys  •  Finite duration of treatment  •  Needle injection  2005
Interferon    •  Once weekly injection  •  Signiﬁ  cant side effects
Alpha-2a    •  Durable response post-treatment  •  65%–70% fail to respond
      (for  responders)  •  High  cost
  •  No  known  resistance   
Telbivudine  Tyzeka  •  Oral  •  Long-term safety and efﬁ  cacy beyond  2006
(TLV or    •  Potent viral suppression     1 year unknown
LdT))    •  Resistance: 4% for HBeAg(+)  •  Efﬁ  cacy to LVD-resistant HBV unknown
       CHB (cf. 9.1% for LVD), 2.7% for
      HBeAg(-) CHB (cf. 9.8% for LVD)
(Conjeevaram and Lok 2003; Marcellin et al 2004; Lau et al 2005; Chae and Hann 2006; Lai et al 2006; Colonno et al 2007)Therapeutics and Clinical Risk Management 2007:3(4) 611
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than each drug (Lau et al 2004). An earlier study comparing 
LVD and ADV to LVD monotherapy showed no beneﬁ  t of 
combination (Sung et al 2003). Nevertheless, Yuen et al (2001) 
showed that if patient’s serum HBV DNA is  103 copies/ml 
at 6th month on LVD therapy, addition of adefovir could 
decrease the chance of LVD resistance which may occur in 
64% of these patients at the end of the year.
Summary-practice guideline for 
HBeAg positive and negative patients
To date, several guidelines for the treatment CHB patients 
(AASLD (Lok and McMahon 2001 and 2004), EASL (The 
EASL Jury 2003), APASL (Liaw et al 2003) and others 
such as KASL guideline (Korean Association for the Study 
of Liver 2004), and Keeffe and his colleagues (Keeffe et al 
2006) are presented. However, there are no uniform guide-
lines globally for the usage of antivirals in the treatment 
CHB at present. Ultimately the ideal antiviral therapy would 
be tailored for individual patients. Physicians may need to 
examine the various guidelines and determine which recom-
mendations are most appropriate for the locale, availability 
of the drugs, and economic situations in which they prac-
tice. Keeffe et al recently suggested cut-off levels of HBV 
DNA as an indication of antiviral therapy of 20,000 IU/mL 
(100,000 copies/mL) for patients with HBeAg(+) CHB and 
2,000 IU/mL (10,000 copies/mL) for HBeAg(–) CHB, both 
with abnormal ALT levels. The newly recommended upper 
normal level of ALT by Keeffe et al is 30 U/L for males and 
19 U/L for females (Prati et al 2002).
At present, LVD, ADV, ETV, LDT or PegIFN can be 
considered as the ﬁ  rst line option except the recent guideline 
proposed by Keeffe and his group in the US (Keeffe et al 
2006). Despite issues with the development of resistance, 
LVD remains an affordable option for CHB therapy for 
patients with limited ﬁ  nancial means. Based on the experience 
by Chae and Hann (2006), patients with low baseline HBV 
DNA ( 6log10 copies/ml) may still beneﬁ  t from LVD as ﬁ  rst 
line therapy. The ultimate goal of antiviral therapy for CHB 
patients lies in halting the progression of liver disease to liver 
cirrhosis and its life threatening complications and in prevent-
ing/reducing the development of HCC. We feel that this goal 
can be achieved with careful, well-informed decision making 
on antiviral therapy and close follow-up of CHB patients.
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